Kornimate/medical-research-clean huggingface dataset:
a randomized pilot trial evaluating the impact of a yoga intervention on cognition in older adults infected with hiv

Conditions: HIV/AIDS; Cognitive Impairment; Aging; Mobility Limitation; Medication Adherence; Depression; Quality of Life; Balance Problems

Summary: approximately 50% of people living with hiv (and as many as 80% over the age of 50) have difficulties with cognitive functions such as memory and thinking that can have a profound negative impact on activities of daily living and quality of life. problems with memory and thinking are also associated with forgetting to take anti-retroviral drugs and experiencing challenges to balance, walking and mental health (anxiety and depression). there is increasing evidence that, in the general population, exercise has positive effects on cognition, physical functioning and mental health. despite the recognition of multiple therapeutic benefits of exercise, little attention has been paid to its possible effects on cognition in people living with hiv. the purpose of the proposed pilot study is to compare the effects of a 12-week, randomly assigned, community-based yoga-mindfulness intervention on cognition, balance, walking, mental health and quality of life in 30 people \>35 years of age living with hiv in the halifax area. yoga is of particular interest because it encompasses not only the physical but also spiritual, emotional, and mental dimensions of life. as such, it has tremendous potential to help stave off some of the devastating consequences of hiv infection.


Eligibility criteria:
inclusion criteria: 1. participant self-report of hiv diagnosis 2. identified cognitive concerns on the c3q (communicating cognitive challenges in hiv questionnaire) 3. residence in the halifax area 4. capacity to provide informed consent 5. aged 35 or older exclusion criteria: * if participants present with contraindications to exercise, they will be excluded from the study. if participants have participated in a yoga program within the past 6 months, they will be excluded.

Keywords: hiv cognitive impairment aging physical activity exercise yoga neuroplasticity
opera study: a study of two dosing regimens of cellcept (mycophenolate mofetil) in kidney transplant patients.

Conditions: Kidney Transplantation

Summary: this study will compare the incidence of acute clinical or subclinical rejection between immunosuppression with cellcept at a starting dose of 3mg po daily with therapeutic drug monitoring and standard immunosuppression with cellcept and a fixed dose of 2g po daily, in kidney transplant recipients receiving induction by anti-irl2, cyclosporine therapy, and early discontinuation of steroids. patients will be randomized to one of the two treatment arms. the anticipated time on study treatment is 52 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, aged 18-75 years of age; * in receipt of first donor kidney; * eligible to receive immunosuppressive treatment comprising irl2, cellcept, cyclosporine and steroids; * eligible to receive oral treatment from the first day post-transplantation. exclusion criteria: * patients receiving a second or subsequent kidney transplant, or multi-organ transplant; * history of malignancy in the last 5 years (except successfully treated squamous cell or basal cell cancer and cervical cancer in situ); * patients with active hepatitis b and/or hepatitis c, or hiv infection.
ffrangio accuracy vs. standard ffr

Conditions: Coronary Artery Disease

Summary: this is a prospective, observational, multi-center, single-arm, clinical trial designed to assess the efficacy of ffrangio in measuring ffr obtained from angiography compared to invasive ffr for diagnosing hemodynamically significant coronary stenosis.


Eligibility criteria:
inclusion criteria: * male or female subjects, \>18 years of age. * patients with stable angina or unstable angina or nstemi, and in whom invasive ffr is being assessed in a non-culprit stenosis in at least one coronary artery. * subject is undergoing invasive ffr with adenosine, atp or papaverine used as hyperemic stimulus. * provides written, informed consent (where required) exclusion criteria: * contraindication for ffr examination or administration of vasodilators. * subject is presenting with acute infarct (stemi) or has documented prior stemi on same side (right/left). * cto in target vessel. * prior cabg, heart transplant or valve surgery, or prior tavi/tavr. * known lvef ≤45%. * arteries supplying akinetic or severe hypokinetic territories if already known based on prior imaging. * timi grade 2 or lower at baseline. * target lesion involves left main (stenosis \>50%). * pci with stent in target vessel in past 12 months, or target vessel involves in-stent restenosis. * severe, diffuse disease defined as the presence of diffuse, serial gross luminal irregularities present in the majority of the coronary tree. * target coronary vessel is supplied by major collaterals.
chest ct biomarkers as prognostic predictors in ssc-ild

Conditions: Systemic Sclerosis

Summary: the goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ild progression, vasculopathy development, and survival in ssc-ild.

interstitial lung disease (ild or lung fibrosis=stiffening of the lungs by scar tissue) develops in over half of patients with systemic sclerosis (ssc). whilst ild remains stable in some patients, at least a third have progressively increasing fibrosis. there is a pressing need for accurate indicators that identify a) patients at higher risk of progression, needing immediate treatment to prevent further irreversible ild; and b) patients at lower risk, not needing treatment. in this study the prognostic potential and accuracy of machine-learning derived biomarkers to evaluate abnormalities that are difficult to quantify visually will be investigated. whether novel high resolution computed tomography (hrct) imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline can predict ild progression, vasculopathy development, and survival will be investigated in a cohort of approximately 1,000 ssc-ild patients. the algorithm scores will be evaluated against survival using cox proportional hazards modelling, while mixed effects model analysis will be used to assess links with change in lung function: forced vital capacity (fvc), diffusing capacity for carbon monoxide (dlco), and carbon monoxide transfer coefficient (kco). the airway algorithm measuring traction bronchiectasis (dilatation of the airways due to surrounding fibrosis) may predict worsening of fvc, reflective of ild progression. the vessel algorithm may predict decline in kco, a marker of pulmonary vascular involvement. exploratory analyses evaluating change in hrct fibrosis extent over time for patients with repeat hrcts will also be performed, and whether composite outcomes of change in hrct and lung function variables improve long term outcome prediction and pave the way to their use in clinical trials and routine clinical use. patients with trivial changes on ct will also be included to assess for very early changes that could be predictive of future decline. these algorithms will be combined with the findings of our previous study, which suggest that a certain type of pattern on ct called uip predicts shorter survival.

Eligibility criteria:
inclusion criteria: * diagnosed with ssc * ≥18 years old * hrct between 01/01/1990 and 31/12/2019 exclusion criteria: * patients who do not have ssc * \<18 years old * lack of availability of hrct imaging data
muscle dysfunction in gastrointestinal or hepatobiliary cancer

Conditions: Cancer; Cancer of Pancreas; Cancer of Liver; Cancer of Esophagus; Cancer of Stomach; Cancer, Metastatic

Summary: purpose: to determine the prognostic properties of a comprehensive evaluation of body composition and physical function in patients with gi-hep cancer from point of diagnosis and throughout the treatment trajectory. gi-hep: patients with tumors of the upper gastrointestinal or hepatobiliary tract, specifically tumors of the esophagus, gastro-esophageal junction, stomach, primary tumors of the liver or biliary tract, as well as colorectal liver metastasis or tumors of the pancreas.

rational: patients diagnosed with gi-hep cancer are faced with poor prognosis. the treatment is demanding and associated with severe deconditioning potentially leading to worse prognostic outcomes. to what extend patients body composition at the point of diagnoses, as well as changes in body composition throughout the cancer continuum is associated with cancer outcomes is currently not well-described, specifically if this should be part of standard clinical evaluation in order to optimize therapy-efficacy. recent findings suggest that pathophysiological alterations in skeletal muscle mass and function can have significant implications for the risk of disease progression and long-term prognosis.

Eligibility criteria:
inclusion criteria: * patients diagnosed with histologically verified gi-hep cancer exclusion criteria: * age: \<18 * pregnancy * physical or mental disabilities precluding physical testing * inability to read and understand danish

Keywords: cancer muscle mass muscle strength complications patient reported outcomes pro physical function
anf-rho in the treatment of chronic neutropenia

Conditions: Neutropenia, Severe Chronic

Summary: a 6 month safety, tolerability, efficacy and pharmacokinetic study with anf-rho to treat patients with chronic neutropenia.

chronic neutropenia patients who are eligible for participation will be screened and enrolled to received open-label anf-rho for a period of 6 months. study participation will be separated into 2 periods, induction (8 weeks) and maintenance (16 weeks). blood samples to measure neutrophil levels and biochemistry labs will be drawn throughout the study to monitor efficacy response and patient safety. pharmacokinetic samples will be collected during both periods and questionnaires will be completed by the patient and investigator for bone pain, quality of life (qol) and injection site reaction.

Eligibility criteria:
inclusion criteria: 1. patients 1 years of age or older 2. patients with established chronic neutropenia defined as median absolute neutrophil count (anc) \< 0.5 x 109/l (both with and without demonstrated genetic lesion) having an indication for treatment, including: independent of hematological parameters, all patients with: shwachman-diamond syndrome (sds), barth's syndrome or other inherited diseases associated with neutropenia (exclude glycogen storage disease 1b) 3. patients on granulocyte-colony stimulating factor (gcsf) \& peg-gcsf treatment are still eligible to participate after a washout period of 7 days, after the stopping of the drug 4. signed and dated informed written consent/assent by the patient/parent 5. women of childbearing potential with a negative serum pregnancy test and using a reliable method of contraception during the study period. male study participants also agreeing to use contraception for the study period. exclusion criteria: 1. evidence of chromosomal abnormalities, myelodysplasia, hematologic malignancy, aplastic anemia, systemic lupus erythematosus, or rheumatoid arthritis (felty's syndrome) or if the neutropenia was drug-induced 2. progressive malignant disease or malignancy history 3. presence of macrophage activation syndrome before the diagnosis of neutropenia 4. clinical significant abnormal renal, cardiac, hepatic or blood coagulation disease. 5. chronic infection such as hepatitis b virus (hbv), hepatitis c virus (hcv) or human immunodeficiency virus( hiv) or history of tuberculosis 6. association with anemia, thrombocytopenia (low blood platelets) before the diagnosis of neutropenia. 7. drug abuse, substance abuse, or alcohol abuse 8. use of any other investigational drug at the time of enrollment, or within 5 half-lives prior to enrollment, whichever is longer 9. patients unwilling and/or who are not capable of ensuring compliance with the provisions of the study protocol 10. women who are pregnant or breastfeeding 11. women of childbearing potential who do not use an approved method of birth control. periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) is not acceptable 12. patients with known dna loss-of-function mutations in gcsfr and runx1 genes
food effect, oral & intravenous pharmacokinetics and absolute bioavailability of bay1834845 including drug-drug interaction with methotrexate

Conditions: Inflammation

Summary: this study is planned to explore the effect of food on the oral pharmacokinetics, the intravenous pharmacokinetics and the absolute bioavailability of bay1834845. furthermore, this study will investigate the effect of bay1834845 on the pharmacokinetics of orally administered methotrexate in healthy male subjects.


Eligibility criteria:
inclusion criteria: * male; healthy according to complete medical history, physical examination, vital signs, 12-lead ecg and clinical laboratory tests as listed in the exclusion criteria given below. * age 18-50 years (inclusive) at the first screening visit. * body mass index: \>=18 kg/m² and \<=30 kg/m². * sexually active men must agree to practice adequate methods of contraception (protection). this applies for the time period between signing of the informed consent form and up to 90 days after the last administration of the study drug(s). exclusion criteria: * any contraindications for intake of bay 1834845 or methotrexate, gastrointestinal, liver, renal, lung or cardiovascular disorders, malignant tumors, known severe allergies, known or suspected immunodeficiency * medication history: drugs known to induce/inhibit liver enzymes * smoking * clinically relevant findings in * physical * ecg, blood pressure * laboratory values * known hypersensitivity to study drug(s)
to evaluate effectiveness of visanne in improving quality of life in asian women with endometriosis

Conditions: Endometriosis

Summary: this study is a prospective observational cohort study. the study will be conducted in routine clinical practice settings. it is planned to enroll 870 patients with endometriosis for whom a decision has been made by the physician to treat with dienogest according to local health authority approved label. it is the aim of this observational cohort study to further characterize the effectiveness of dienogest in improving quality of life and long-term safety in routine clinical practice setting. endometriosis is chronic and progressive disease and there is unmet need for long-term treatment. visanne® with proven efficacy and safety, can be good option for long-term treatment, however, experience with visanne® beyond 15 month is limited. and long-term up to 24 months data on effectiveness and safety of visanne would support the long-term treatment strategy for endometriosis management in the clinical practice.


Eligibility criteria:
inclusion criteria: * asian female patients at least 18 years of age * clinical or surgical diagnosis of endometriosis (depending on local approved indication) : clinical diagnosis by suggestive symptoms and positive finding in imaging study (chocolate cyst) * patients with endometriosis associated pelvic pain * decision taken by the physician to newly prescribe visanne® * availability of a signed informed consent exclusion criteria: * patients participating in an investigational program with interventions outside of routine clinical practice * patients for whom any of contraindication listed in the local summary of product characteristics (spc) apply.
a non-inferiority evaluation of a smart-phone based cervical imaging device.

Conditions: Cervical Cancer

Summary: when a woman has an abnormal pap smear or tests positive for a high risk strain of the hpv virus, the current standard of care includes culposcopic examination of the cervix with biopsy. a culposcope is essentially a microscope for examining the cervix. culposcopes cost $5-10,000 each. the device being tested in this trial is an adaptor for a smart phone that will cost \~ $125. the larger goal of this line of studies see if the images obtained using the smart phone adaptor are non-inferior to those obtained with standard culposcopes. if the device is found to provide images equal to those of standard culposscopes, it could save thousands of dollars in healthcare expenditure currently that go to the purchase and maintenance of culposcopes. this has potential world-wide applications, especially for resource poor countries. this initial trial is a non-inferiority trial to compare the images obtained with the smart phone based device of those obtained by a standard culposcope

see above.

Eligibility criteria:
inclusion criteria: adult women with abnormal pap smear or hpv virus testing referred for culposcopy - exclusion criteria: none -

Keywords: cervical cancer screening,colposcopy,smartphone
cerebral and cognitive impact of female professional soccerpractice

Conditions: Traumatic Chronic Encephalopathy

Summary: the objective of this study is to evaluate, using mri, the microstructural consequences and the onset of any cognitive impairment in female professional soccer players at the end of their career, who have experienced repeated minor head injuries. over the long term, these head injuries could lead to morphological lesions and have an impact on female soccer players' cognitive skills. the main evaluation criterion corresponds to the modifications found on mri in the female professional soccer player group (diffusion tensor, cerebral perfusion, fmri, cerebral volumetry and cortical thickness, spectroscopy, susceptibility imaging). this is an exposure/nonexposure study assessing the onset of mri abnormalities (diffusion tensor, cerebral perfusion, fmri, volumetry and cortical thickness, spectroscopy, susceptibility imaging) in female professional soccer players exposed to repeated mild head injuries, who are either at the end of their career or retired for approximately 10 years, compared to high-level athletes not exposed to head injuries.


Eligibility criteria:
inclusion criteria: * exposed high-level athletes: female professional soccer players at the end of their career (32- years old) playing in france ligue 1 or 2 exposed to repeated mild head injuries with no history of severe head injury or cerebral * female high-level athletes not exposed to repeated mild head injuries: control group paired for age with female professional soccer players, who have never regularly participated in sports exposing them to head injuries (notably rugby, basketball, handball, american football, hockey, combat sports, etc.) and who have no history of head injury, even mild. female professional tennis players or former players will be preferentially recruited. exclusion criteria: * refusal to be informed of abnormalities on mri * incapacity to give informed consent or under a legal protection order; * history of cerebral concussion including the presence after head shock of one or more of the following signs or symptoms: a period of confusion or disorientation, a period of loss of consciousness of 30 minutes or less, post-traumatic amnesia not exceeding 24 hours * history of severe head/brain injury; * history of neurological or psychiatric disorder; * known cerebral abnormality diagnosed by an imaging exam (ct or mri); * history or regular or occasional consumption of drugs, unweaned active smoking or weaned for less than 1 year, excessive consumption of alcohol (\> 20 g alcohol per day, evaluated with the formula "degree of alcohol × volume in cl × 8/1000"), weaned or not. * usage of medication targeting the central nervous system in the 2 weeks preceding inclusion in the study; * prior history of severe hypertension, diabetes, chronic heart disease, progressive or disabling disease; * contraindication to mri (claustrophobia, implanted material not compatible with mri, refusal to be informed of abnormality discovered on mri)

Keywords: soccer mri head traumatism neuropsychology traumatic chronic encephalopathy
mesh debate awareness among non-urogynecologists. a practical survey study.

Conditions: Pelvic Organ Prolapse; Urinary Incontinence; Complication of Surgical Procedure

Summary: this study evaluates the awareness of mesh discussions in urogynecology among non-urogynecologists. a web-based questionnaire will be sent to four groups. group-1 is king's college hospital doctors. group-2 is uludag university hospital doctors. group-3 is doctors from the united states, and group-4 is doctors from all over the world.

there has been a great deal of discussion about mesh complications in urogynecology. during the following decade, vaginal mesh operations for pelvic organ prolapse increased exponentially all over the world, particularly in the united states. once the complications started to increase, the publication of mesh-related complications on social and broadcast media and the increase of medico-legal claims the united states led to an extensive fda (food and drug administration) restriction on vaginal mesh procedures in 2013. on january 5, 2016, the fda reclassified surgical mesh for transvaginal repair of the pelvic organ prolapse into class iii, which require premarket approval. finally, on april 16, 2019, the fda ordered all manufacturers of urogynecological mesh intended for transvaginal repair to stop selling and distributing their products immediately. however, awareness of the other doctors in branches of medicine outside of gynecology and urology is unknown.

Eligibility criteria:
inclusion criteria: * doctors from all branches of medicine * basic sciences: immunology, medical biochemistry, microbiology and infectious diseases, forensic medicine, family medicine, public health, medical genetics, medical pharmacology. * pediatrics: pediatric allergy, pediatric respiratory, pediatric dentistry, pediatric endocrinology, pediatric gastroenterology and nutrition, pediatric haematology, pediatric nephrology, pediatric neurology, pediatric oncology, pediatric ophthalmology, pediatric surgery, child and adolescent psychiatry, pediatric orthopedics. * basic internal medicine specialties: gastroenterology, medical oncology, rheumatology, hematology, nephrology, endocrinology * other internal medicine specialties: neurology, nuclear medicine, radiology, radiation oncology, psychiatry, sport medicine, respiratory medicine, physical medicine and rehabilitation, geriatrics, dermatology, cardiology * surgical departments: emergency and accident medicine, heart and vascular surgery, ophthalmatology, orthopedics and traumatology, plastic and reconstructive surgery, medical pathology, anesthesiology and reanimation, neurosurgery, general surgery, chest surgery exclusion criteria: * obstetricians and gynaecologists, * urogynecologists, * urologists, * perinatologists , * gynecological oncologists, * doctors from reproductive endocrinology and infertility, * uro-oncologists * andrologists.

Keywords: mesh complications social media awareness knowledge of doctors